Acquired sensory neuronopathies …

Jean-Christophe Antoine MD

Neuroimmunology

Updated 04.07.2024
Released 05.22.2001
Expires For CME 04.07.2027

Acquired sensory neuronopathies

Author: Jean-Christophe Antoine MD

See Contributor Disclosures

Editor: Francesc Graus MD PhD

Acquired sensory neuronopathies

In This Article

Quick Link

Introduction

Overview

Acquired sensory neuronopathies depend on a primary involvement of sensory neurons in dorsal root ganglia leading eventually to a definitive and irreversible degeneration of the cell body (31; 65; 25). They include toxic, infectious, and dysimmune mechanisms, although an important proportion remains idiopathic after an extensive workup. The differential diagnosis includes genetic sensory neuronopathies and sensory ataxic neuropathies that may resemble acquired sensory neuronopathies (18). A short therapeutic window before definitive neuron degeneration warrants that all effort should be made to obtain an early diagnosis of these disorders.

Key points

	• Many acquired sensory neuronopathies are probably immune-mediated.
	• Serum neural antibodies are important biomarkers for particular types of sensory neuronopathies.
	• An early diagnosis is warranted to treat the patient before neuron cell death.

Historical note and terminology

The concept of sensory neuronopathy or ganglionopathy was first developed by Dereck Denny-Brown in 1948 in his seminal description of the first pathologically description of sensory neuronopathies due to a remote effect of cancer (15). The term “neuronopathy” is used to indicate that the neuron cell body is the target of the disorder at the difference of “peripheral neuropathy”, which designates diseases involving the axon or myelin sheath of the neuron peripheral process.

The main difficulty with sensory neuronopathies is that the direct exploration of sensory ganglia is very difficult and that we can only rely on indirect arguments to ascribe a given disorder to a degeneration of sensory neurons because dorsal root ganglia biopsy cannot be routinely performed. Another problem is that depending on the etiology, the lesioning process may sometimes extend to other part of the nervous system so that the disorder may not be purely sensory. Beyond the dorsal root ganglia, the most frequently affected structures are the autonomic nervous system, motor neurons, peripheral nerves, and the cerebellum. Of course, this clearly depends on the etiology of the sensory neuronopathy. In particular in genetic diseases, sensory neuronopathy is frequently only one component of the disorder. On another side, inflammatory and paraneoplastic sensory neuronopathies are often associated with autonomic nervous system involvement.

The last level of complexity is that the sensory neuron population is heterogeneous, with at least two distinct morphological and functional groups of neurons: those involved in thermal and pain sensation whose axon is unmyelinated and those involved in proprioception and superficial tact with a myelinated axon. However, it is now established that there exist at least 11 subtypes of sensory neurons based on their function, fiber type, receptors, developmental pathway, and molecular expression in the adult (72). This explains that some disorders may specifically or predominantly target 1 group of neurons, resulting in a purely or predominantly ataxic or painful neuropathy.

Here, we will focus on acquired sensory neuronopathies and only mention the hereditary forms that may be difficult to distinguish from acquired sensory neuronopathies.

Clinical manifestations

Presentation and course

Sensory neuronopathies share a general clinical and electrophysiological pattern which is typically that of a purely sensory neuropathy with a nonlength dependent distribution of sensory loss (06; 31). The four limbs are usually affected mostly in their distal part (feet and hands). The disorder may in addition involve the face and the trunk. The loss of large sensory neurons results in ataxia that usually predominates in the lower limbs, resulting in ataxic gate and Romberg sign. In some cases, the disorder is so severe that the patient is unable to stand up and walk. Deep or superficial sensory loss also affects the upper limbs, which may result in severe disability, with some patients being unable to perform any purposeful movement with their hands. Pseudo athetoid movements of fingers or hands are a manifestation of deep sensation loss. Damage to small neurons induces a loss of thermal and pain sensation. Neuropathic pain is frequent in this case, and trophic skin lesion may appear, particularly with genetic sensory neuronopathies.

The initial distribution of sensory disturbances and their extension with time are strongly dependent on the underlying mechanism of the disease, which helps to orientate the etiological diagnosis. Thus, a symmetrical distribution starting in the lower limbs and a prominence of deep sensation loss are common with genetic or toxic sensory neuronopathies but may also be encountered in some idiopathic cases, particularly in the elderly. In opposition, asymmetry or a multifocal distribution sometimes mimicking mononeuritis multiplex and early involvement of the hands or face characterize inflammatory sensory neuronopathies including paraneoplastic sensory neuronopathies and sensory neuronopathies associated with autoimmune diseases. But with time, the distribution usually becomes more symmetrical and diffuse. An acute or subacute evolution characterizes chemotherapy-induced, infectious, or paraneoplastic sensory neuronopathies whereas a progressive course is the hallmark of genetic diseases but also occurs in dysimmune or idiopathic sensory neuronopathies.

Prognosis and complications

Prognosis is quite variable. Some patients may have a restricted and limited form, whereas others may develop a very disabling disorder and become chair-bound. Acute form, sometimes classified as sensory Guillain-Barré syndrome, may not recover. Association with a severe autonomic neuropathy may have a bad prognosis because patients develop severe orthostatic hypotension, cardiac arrest, pseudo-digestive obstruction (typically paraneoplastic sensory neuronopathies), or sudomotor crisis with intolerance to heath. Small fiber involvement may result in chronic skin ulcerations and indolent burns.

Clinical vignette

A 53-year-old woman with chronic alcoholic consumption and smoking complained of two years of eye dryness. In March, paresthesia and dysesthesia appeared within a few days in the first three fingers of her right hand and rapidly reached all the others. A few weeks later symptoms extended to the left hand. She experienced difficulties with buttons, writing, and manipulating small objects due to sensory loss and pain elicited by contact. In April, similar symptoms appeared in the feet and gait became unsteady. The patient was referred in June. Although her gate was slightly ataxic and symptoms persisted in the hand, the patient was totally independent. Tendon reflexes were diffusely abolished. Vibration sense was abolished and pain sensation reduced in the four extremities. Electroneuromyography showed a severe reduction of all the tested sensory action potentials in the four limbs whereas motor conduction velocities were normal. Such a pattern, which fulfills the diagnostic criteria of possible sensory neuronopathies (score = 12.7) (see infra) ruled out an alcoholic length-dependent polyneuropathy. A diagnosis of sensory neuronopathy was established and a biological workup in search of the underlying etiology was performed and revealed to be negative: there was no sicca syndrome, no monoclonal gammopathy. Sjögren syndrome associated anti-SS-A and SS-B antibodies were negative as were the search for paraneoplastic antibodies (Hu, Ma2, CRMP5, amphiphysin, Yo, Ri antibodies), antibodies associated with hepatitis, celiac disease, and antiganglioside antibodies. Viral serology was negative. However, CSF examination showed normal protein concentration with an oligoclonal pattern of IgGs and 10 lymphocytes/mm3 (N < 1). This joined with the subacute onset of the disorder and the presence of pain led to suspect a seronegative paraneoplastic sensory neuronopathy. FDG-PET scanner was performed and revealed an abnormal uptake in the left breast. Biopsy disclosed an adenocarcinoma. The patient was treated for her cancer. The neuropathy slightly improved and then remained stable. A final diagnosis of paraneoplastic sensory neuronopathy was retained.

Biological basis

Etiology and pathogenesis

Paraneoplastic sensory neuronopathies: subacute paraneoplastic sensory neuronopathy. Sensory neuronopathy is the most frequent paraneoplastic neurologic syndrome, representing 24% of cases in the series of about 1000 paraneoplastic patients of the PNS Euronetwork group (20). It is thought to be a T cell mediated disorder targeting antigens expressed by the tumor, which are also expressed by neurons in dorsal root ganglia (14). The most frequent of these onconeural antigens is HuD (23). The onset is subacute or rapidly progressive but indolent and protracted courses over several months may occur (22). Sensory loss is frequently multifocal or asymmetrical, and as a rule, involves the upper limbs in a nonlength dependent distribution. The face, chest, or trunk can also be concerned. Although large and small sensory neurons are simultaneously affected, in some cases, lesions predominate on one type of neurons resulting in a mostly ataxic sensory neuronopathy or a mostly painful small fiber neuropathy. The autonomous nervous system is involved in 20% to 24% of patients and manifests as gastrointestinal dysmotility, orthostatic hypotension, arrhythmia, or urinary dysfunction (23).

On the electrophysiological point of view, beside a severe alteration of sensory action potentials, mild modifications of motor conduction velocities and neurogenic needle recordings are not infrequent (07; 54). These changes result from subclinical involvement of lower motor neurons in the spinal cord and the extension of the inflammatory reaction into the roots and peripheral nerves. The CSF usually shows elevated protein concentration, pleocytosis, and oligoclonal bands. In about 90% of cases sensory neuronopathy precedes by several months the appearance of the underlying tumor or its relapse. In 70% to 80% of cases, it is a small cell lung cancer. Most patients have Hu antibodies. Amphiphysin or CV2/CRMP5 antibodies occur in 5% to 10% of cases with or without Hu antibodies and in 10% to 16% of patients onconeural antibodies are not found. These patients usually have another type of tumor including breast cancer or Hodgkin disease (20).

The management of paraneoplastic sensory neuronopathies is difficult. Immunomodulatory treatments including prednisolone, intravenous immunoglobulins, plasma exchanges, cyclophosphamide, tacrolimus, and rituximab alone or in combination have been tested in open and uncontrolled small series. Their efficacy is not clearly proven although some patients improve (03). Tumor treatment is probably the best way of stabilizing the disease so that all the effort should be made to obtain an early diagnosis of the cancer (23). Among possible investigations, FDG-PET scanner is certainly the first-line exam. In a patient with onconeural antibodies, if the initial workup is negative it should be repeated after three months and then every six months for four years (70).

Toxic sensory neuronopathy. High doses of pyridoxine have been demonstrated to induce sensory neurons necrosis in rats (62). In humans, chronic consumption of pyridoxine induces an irreversible ataxic neuropathy. The effect is probably dose-dependent and the toxic dose may vary between 200 and 6000 mg/day.

The most frequent cause of toxic sensory neuronopathy depends on the use of platinum salt for the treatment of cancer (30). Cisplatin and oxaliplatin are more toxic than carboplatin (38). The cumulative toxic dose is 300 mg/m2 for cisplatin and oxaliplatin and 400 mg/m2 for carboplatin. The onset is usually subacute, with severe paresthesia and ataxia in the four limbs. Oxaliplatin also induces transient mouth and throat sensory symptoms aggravated by exposure to cold in the hours following infusion (38). A so-called coasting phenomenon due to a delayed release of the toxic drug accumulated in tissues is responsible for the development or worsening of the neuropathy up to several weeks after treatment interruption so that an arrest of treatment should be considered as soon as progressing sensory symptoms appear (02). In animals, platinum salt induces multiple nuclear and mitochondrial DNA damages that may eventually result in sensory neurons apoptosis (43; 68). This explains that the clinical recovery is frequently incomplete. In patients with paraneoplastic sensory neuronopathy, the use of platinum salt for the treatment of cancer may be problematic, and treatment with the less toxic compound should probably be preferred.

Infectious sensory neuronopathy. This is probably a rare condition. The most numerous cases, including pathological demonstration of inflammatory changes in the dorsal root ganglia, have been published in the setting of HIV infection before the era of antiviral treatments. The onset is acute or chronic although the viral gp120 protein can bind the neurons. The mechanism is more probably an autoimmune disorder triggered by the virus present in endoneurial macrophages (13). Occasional cases of an acute nonlength dependent pure sensory neuropathy, thus probably true sensory neuronopathy, have been reported with Epstein-Barr virus (59), human T-lymphotropic virus (40), herpes zoster virus, or Zika virus infection (41).

Sensory neuronopathies with systemic autoimmune diseases. Sensory neuronopathies have mostly been reported in association with Sjögren syndrome (24; 47) and more rarely with autoimmune hepatitis (46; ), celiac disease (17; 26), lupus, or other unclassified connective diseases. The best studied cases are those with Sjögren syndrome for which several series have been published, some with pathological demonstration of specific inflammatory dorsal root ganglia lesions (24; 47). The onset is usually chronic and symmetrical, but some patients may follow a more rapid course. In most cases, ataxia and loss of proprioception are predominant but some patients, may have pure or predominant involvement of small neurons with pain (47; 21; 27). In both cases the distribution is similar, with constant involvement of the four limbs and in 30% to 60% of cases of the face or trunk. Autonomic neuropathy including Adie or Argyll Robertson pupils, orthostatic hypotension, and anhidrosis occur in about 70% of patients (47). Although it has not been demonstrated that the painful form is associated with dorsal root ganglia lesions, this is highly probable. Changes in dorsal root ganglia are relatively similar to that observed in paraneoplastic sensory neuronopathy with an infiltration of T cells in contact of degenerating sensory neurons (24; 47). Sensory neuronopathy frequently precedes by months of years the diagnosis of Sjögren syndrome so that investigation must be regularly renewed in search of a sicca syndrome or SS-A or SS-B antibody positivity. As with paraneoplastic sensory neuronopathy, different immunomodulatory treatments have been used in retrospective and uncontrolled series. Some patients are said to improve with intravenous immunoglobulins or steroids (47; 57). Immunosuppressants should probably be used with some caution in patients with Sjögren syndrome because lymphoma occurs with a higher frequency in this disorder.

Sensory neuronopathies and antidisialosyl ganglioside antibodies. Polyclonal IgM antibodies directed toward disialosyl ganglioside including GD1b, GT1a, and GD3 occur more frequently in chronic ataxic sensory neuropathies (64) whereas antidisialosyl ganglioside monoclonal IgM recognizing in addition to GQ1b are associated with CANOMAD (chronic ataxic neuropathy, ophthalmoplegia, M-protein, cold agglutination, and antidisialosyl antibodies) (73). These disorders are probably heterogeneous because the electroneuromyography may alternatively show features consistent with a primary demyelinating process or a sensory neuronopathy. In addition, autopsy studies in two cases with antidisialosyl antibodies found predominant demyelination in the dorsal roots (53), whereas the other showed involvement of neurons in the dorsal root ganglia (44). Rabbit immunization with GD1b has been reported to induce dorsal root ganglia lesions, but this could not be reproduced (32). Thus, the exact underlying process in these disorders remains unclear.

Idiopathic sensory neuronopathy. The majority of sporadic sensory neuronopathies remain idiopathic after an extensive workup (05). These cases may present with an acute (74; 28), subacute (61), or slowly progressive course (12). Some patients may have subtle findings of an underlying unspecific associated immune context such as low levels of antibodies associated with systemic autoimmune disease or oligoclonal bands in the CSF (60). These neuropathies may also occur with autonomic neuropathy. Before considering a sensory neuronopathy as idiopathic it should be kept in mind that genetic disease such as Friedreich ataxia (56), or CANVAS (cerebellar ataxia, neuropathy, vestibular areflexia syndrome) may present in adult patients without family history (67). Similarly, the sicca syndrome may appear several years after the onset of sensory neuronopathy, and the criteria of Sjögren syndrome may be reached very late in the evolution of the neuropathy (47). CANVAS is now recognized as a frequent cause of sporadic sensory neuronopathy of adult onset. In some series, it may account for 30% of apparently idiopathic cases. Preserved tendon reflexes and a long preceding history of chronic cough are suggestive of CANVAS. Things are complicated by the fact that patients with CANVAS may also develop Sjögren syndrome (11).

A subgroup of idiopathic sensory neuronopathy is probably immune-mediated, as shown by a few pathological studies of dorsal root ganglia. Changes are very similar to that observed in paraneoplastic sensory neuronopathy or sensory neuronopathy with Sjögren syndrome with degeneration of sensory neurons in presence of infiltrating lymphocytes, which when tested are cytotoxic T-cells (10; 28). These cases correspond to acute, subacute, or chronic sensory neuronopathy with or without autonomic neuropathy, and they may account for about 30% of apparently idiopathic cases (10; 60). The difficulty is that only a biopsy of a dorsal root ganglion may theoretically confirm the diagnosis, which of course cannot be recommended. Thus, there is a need for biomarkers, and two antibodies have been proposed as such biomarkers.

Antibodies toward the intracellular domain of the fibroblast growth factor receptor 3 (FGFR3) have been reported in a series of patients with sensory neuropathy (01; 69). Patients with this antibody have a nonlength dependent sensory neuropathy in 89% of cases and met the criteria for sensory neuronopathy in 64% of cases and small fiber neuropathy in 17% of cases (69). The antibodies were the only marker of disimmunity in 66% of patients, and the course was mostly chronic. Other studies have linked anti-FGFR3 antibodies to a broader range of neuropathies (29; 52; 71). The methodology employed for antibody detection is undoubtedly critical for ensuring result specificity (49). Some reports have suggested that patients with anti-FGFR3 antibodies may improve with intravenous immunoglobulins (29). However, the study of Tholance and colleagues did not confirm this finding, as there was no superiority of steroids, intravenous immunoglobulins, or immunosuppressants over each other in patients who received immunomodulatory treatments (69).

Antibodies against argonaut (AGO) proteins 1 and 2, initially described in patients with lupus or Sjögren syndrome, have been identified in inflammatory neurologic disorders, Sensory neuronopathy is the most frequent among them (16; 50). Compared to patients with sensory neuronopathy and no anti-AGO antibodies, those with anti-AGO antibodies exhibited a more severe disease and a higher likelihood of developing Sjögren syndrome. Interestingly, patients with anti-AGO antibodies showed a more favorable response to intravenous immunoglobulin, and the presence of these antibodies was predictive of treatment response. These findings, based on a limited number of patients, require confirmation in larger studies.

Both anti-FGFR3 and anti-AGO antibodies are not specific to sensory neuronopathy, but they are probably helpful to identify an otherwise unapparent underlying disimmune background in patients with apparently idiopathic sensory neuronopathy.

Differential diagnosis

Differential diagnosis mostly includes other ataxic neuropathies and nonacquired sensory neuronopathies. CIDP or anti-MAG monoclonal IgM neuropathies are not difficult to differentiate when the electroneuromyography is clearly demyelinating. Things are more difficult with the proximal form of ataxic CIDP in which demyelination is almost limited to the plexus or roots (66). In this case, motor conduction velocities may be normal but sensory action potentials are not severely altered and somatosensory evoked potentials show delayed potential at the level of plexus or spinal cord entry. Plexus and root MRI is probably the best tool to diagnose these forms by showing enlarged plexus or nerve roots with gadolinium enhancement. However, it may sometimes be very difficult to differentiate sensory neuronopathies from pure sensory CIDP. In this case nerve biopsy may be recommended. B12 deficiency may also mimic sensory neuronopathies all the more so because T2-weighted MRI usually shows hyperintensities in the posterior column of the cervical spinal cord. Sensory nerve vasculitis may also be difficult to differentiate, as acquired inflammatory sensory neuronopathy can have an initial multifocal distribution. The differential diagnosis may even be complicated by the fact that nerve biopsy may show vasculitis in dysimmune sensory neuronopathy.

It may sometimes be difficult to distinguish acquired from hereditary sensory neuronopathy. Sensory neurons are involved in a host of genetic diseases but usually as a component of a complex disorder that involves different neural or nonneural structures. Some of them may present as ataxic sensory neuronopathy over several months or years before extension of symptoms to other systems and therefore may be misdiagnosed as acquired sensory neuronopathy (Table 1), particularly with an adult onset and a presentation of sporadic case. This particularly occurs with Friedreich ataxia (55; 56), SANDO syndrome due to POLG mutation (63; 36), and CANVAS (67; 58; 11). It may be difficult to differentiate clinically cerebellar ataxia from proprioceptive ataxia when the two simultaneously occur as in Friedreich ataxia and CANVAS. CANVAS may present as recessive or sporadic cases with late onset sensory neuronopathy. Vestibular areflexia is inconstant and chronic cough present in about one third of cases may precede the onset of the neuropathy by several years (11). Very rare cases of sensory neuronopathy have been reported in the setting of hereditary amyloid neuropathy due to transthyretin gene mutations (39).

Table 1. Hereditary/Genetic Sensory Neuronopathies That May Present at Least For a Time as Sporadic Cases of Adult Onset Sensory Neuropathy

Syndrome	Age at onset	Transmission	Clinical manifestation	Gene
POLG-related ataxia neuropathy spectrum, SANDO	variable, including late onset	variable, mostly sporadic	ataxic neuropathy, epilepsy (66%), ophthalmoplegia (50%). SANDO: sensory ataxia neuropathy, dysarthria, ophthalmoplegia	POLG
CANVAS (cerebellar ataxia, neuropathy, vestibular areflexia syndrome)	Adult 35- to 75-years-old	recessive or sporadic	vestibular areflexia 50% of cases, cerebellar atrophy 80%, chronic cough 30%, sensory neuropathy 100%	RFC1
Friedreich ataxia	teenage and adulthood	recessive	cerebellar and sensory ataxia followed by pyramidal tract and optic nerve involvement. Diabetes mellitus, myocardiopathy	FXN

Diagnostic workup

Paraclinical investigations for the diagnosis of sensory neuronopathies. Electroneuromyography typically shows a severe reduction or absence of sensory action potentials in the four limbs with normal or almost normal motor conduction velocities (06). However, subtle motor abnormalities may occur with most of the causes of sensory neuronopathy as minor to mild reduction of motor action potentials and motor conduction velocities or presence of mild neurogenic changes on needle examination (07; 08). These motor changes should be interpreted after taking into account the clinical pattern of the neuropathy and the severity of sensory action potential abnormalities to not miss the diagnosis of sensory neuronopathy .

Sensory evoked potentials have been proposed to investigate the dorsal root ganglia because they can explore the proximal peripheral process of large sensory neurons from plexus to spinal cord entry and their spinal cord central process (34). However, they need a specific recording methodology (51) and the persistence of a sufficient number of sensory neurons to be elicited. In addition, it may be difficult to differentiate a demyelinating disorder of the proximal part of peripheral nerves from a disorder affecting the dorsal root ganglia.

Laser-evoked potentials (37) and skin biopsy (35; 21) can be used to demonstrate a nonlength dependent distribution of small fiber loss. But if nonlength dependent small fiber neuropathies have been attributed to dorsal root ganglia involvement, this has not been pathologically demonstrated yet.

Spinal cord MRI (09) may show the degeneration of the central process of large sensory neurons in the dorsal column appearing as a T2-weighted signal hyperintensity at the level of the cervical spinal cord (33; 48; 19). This may be associated to some degree with spinal cord atrophy (19). However, this is inconstant and not specific to sensory neuronopathy because, for example, B12 deficiency induces T2-weighted hypersignal.

Nerve biopsy is not useful for the positive diagnosis of sensory neuronopathy (12). When performed it shows fiber loss and ongoing axonal degeneration whose severity depends on the course of the neuropathy. It is more interesting for the differential diagnosis with forms of purely sensory chronic inflammatory demyelinating polyneuropathy or vasculitis. Only dorsal root ganglia biopsy may be able to demonstrate the degeneration of sensory neurons with a secondary proliferation of satellite glial cells surrounding neurons resulting in the formation of Nageotte nodules. However, dorsal root ganglia biopsy cannot be recommended as a routine procedure.

The diagnostic strategy of sensory neuronopathies.

Differentiating sensory neuronopathies from other sensory neuropathies. Asbury once proposed that a nonlength dependent sensory neuropathy with pure or almost pure and severe sensory action potential alteration is a sensory neuronopathy but these criteria were never tested (06). We published another set of criteria (Table 2) (08) which tested on a large external population of patients with sensory neuropathy originating from neuromuscular diseases centers, who proved to have 90% sensitivity and 85% specificity against the expert diagnosis (05). These criteria only rely on clinical and electroneuromyography data that are easy to obtain.

Table 2. Diagnostic Criteria of Sensory Neuronopathy

Step A. In a patient with a clinically pure sensory neuropathy
a diagnosis of sensory neuronopathy is considered as possible if total score is > 6.5		Points
(a) Ataxia in the lower or upper limbs at onset or full development of the neuropathy	□	+3.1
(b) Asymmetrical distribution of sensory loss at onset or full development of the neuropathy	□	+1.7
(c) Sensory loss not restricted to the lower limbs at full development	□	+2.0
(d) At least 1 sensory action potential absent or 3 sensory action potentials < 30% of the lower limit of normal in the upper limbs, not explained by entrapment neuropathy	□	+2.8
(e) Fewer than 2 nerves with abnormal motor nerve conduction study in the lower limbs	□	+3.1
Total
Step B. A diagnosis of sensory neuronopathy is probable if: 1) the patient’s score is greater than 6.5; 2) if the initial workup does not show biological or electroneuromyography findings (conduction blocks, temporal dispersion) excluding sensory neuronopathy; and 3) the patient has one of the following disorders: onconeural antibodies or a cancer within five years, cisplatin treatment, or Sjögren syndrome (or if MRI shows high signal in the posterior column of the spinal cord).
Step C. A diagnosis of sensory neuronopathy is definite if dorsal root ganglia degeneration is pathologically demonstrated, although dorsal root ganglia biopsy is not recommended.
Remarks. Full development of the neuropathy corresponds to a stage of the neuropathy at which sensory symptoms have spread and reached a significant extension. Onconeural antibodies include at least anti-Hu, CRMP5, Yo, Ri, Tr, and amphiphysin antibodies. Within five years includes before or after the neuropathy onset.
Electroneuromyography. SAP: sensory action potential, CMAP: compound motor action potential, NCS: nerve conduction study, MCV: motor conduction velocities, LLN: lower limit of normal; Abnormal if CMAP or MCV > 95% of LLN, distal latencies 110% of LLN, or F waves latency >110% of LLN.

Searching for the underlying cause of the sensory neuronopathy. The second step is the etiological diagnosis once the diagnosis of sensory neuronopathy is established. A study addressed the question of the etiological diagnosis of sensory neuronopathy and proposed a strategy that was checked against an internal and external population using multiple correspondence analysis with 95% sensitivity (see Figure 1 below). In a first step a patient with sensory neuronopathy according to the criteria should be investigated with a least a determination of B12, SS-A, SS-B, hepatitis associated antibodies, FGFR3 and AGO antibodies, onconeural antibodies and monoclonal gammopathy. A positivity of one of these tests orientates the etiological diagnosis. If this workup is negative, one has to take into account the evolution of the sensory neuronopathy and its clinical presentation.

With an acute or subacute course, an age over 60 years, an inflammatory CSF, or a marked pain point toward a seronegative paraneoplastic sensory neuronopathy (about 10% of cases), an FGF-PET scanner must be performed. If this is negative, one should consider infectious, dysimmune, or idiopathic sensory neuronopathy. If the progression is slow with predominant ataxia and few positive symptoms such as paresthesia and pain, three possibilities should be considered: (1) genetic sensory neuronopathy particularly if there are family cases and an early onset. Chronic cough may also point toward a genetic sensory neuronopathy (CANVAS). In these cases, genetic tests should be considered; (2) dysimmune sensory neuronopathy, particularly if the onset is asymmetrical or multifocal and the face or trunk are involved. Patients with this pattern should regularly be investigated for Sjögren syndrome or other autoimmune diseases that may appear years after the neuropathy onset; (3) finally, an important subgroup will remain unexplained, which as discussed probably conceals at least cases of dysimmune or genetic sensory neuronopathy.

General strategy for the diagnosis of sensory neuronopathies

Blue arrow indicates a “yes” condition and the white arrow a “no” condition. (Contributed by Dr. Jean-Christophe Antoine.)

References

01: Antoine JC, Boutahar N, Lassabliere F, et al. Antifibroblast growth factor receptor 3 antibodies identify a subgroup of patients with sensory neuropathy. J Neurol Neurosurg Psychiatry 2015;86(12):1347-55. PMID 25628376
02: Antoine JC, Camdessanche JP. Peripheral nervous system involvement in patients with cancer. Lancet Neurol 2007;6(1):75-86. PMID 17166804
03: Antoine JC, Camdessanche JP. Treatment options in paraneoplastic disorders of the peripheral nervous system. Curr Treat Options Neurol 2013;15(2):210-23. PMID 23307613
04: Antoine JC, Robert-Varvat F, Maisonobe T, et al. Identifying a therapeutic window in acute and subacute inflammatory sensory neuronopathies. J Neurol Sci 2016;361:187-91. PMID 26810539
05: Antoine JC, Robert-Varvat F, Maisonobe T, et al. Testing the validity of a set of diagnostic criteria for sensory neuronopathies: a francophone collaborative study. J Neurol 2014;261(11):2093-100. PMID 25108558
06: Asbury AK. Sensory neuronopathy. Semin Neurol 1987;7(1):58-66. PMID 3332448
07: Camdessanche JP, Antoine JC, Honnorat J, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain 2002;125(Pt 1):166-75. PMID 11834602
08: Camdessanche JP, Jousserand G, Ferraud K, et al. The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain 2009;132(Pt 7):1723-33. PMID 19506068
09: Casseb RF, Martinez AR, de Paiva JL, Franca MC, Jr. Neuroimaging in sensory neuronopathy. J Neuroimaging 2015;25(5):704-9. PMID 25678358
10: Colli BO, Carlotti CG Jr, Assirati JA Jr, et al. Dorsal root ganglionectomy for the diagnosis of sensory neuropathies. Surgical technique and results. Surg Neurol 2008;69(3):266-73;discussion 273. PMID 17597195
11: Cortese A, Curro R, Vegezzi E, Yau WY, Houlden H, Reilly MM. Cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS): genetic and clinical aspects. Pract Neurol 2022;22(1):14-8. PMID 34389644
12: Dalakas MC. Chronic idiopathic ataxic neuropathy. Ann Neurol 1986;19(6):545-54. PMID 3014995
13: Dalakas MC, Cupler EJ. Neuropathies in HIV infection. Baillieres Clin Neurol 1996;5(1):199-218. PMID 8732208
14: Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol 1999;9(2):275-84. PMID 10219745
15: Denny-Brown D. Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psychiatry 1948;11(2):73-87. PMID 18861108
16: Do LD, Moritz CP, Muniz-Castrillo S, et al. Argonaute autoantibodies as biomarkers in autoimmune neurologic diseases. Neurol Neuroimmunol Neuroinflamm 2021;8(5):e1032. PMID 34321331
17: Dominguez-Gonzalez C, Martinez-Salio A, Gordo-Manas R, Ballesteros-Plaza L, Hernandez-Lain A, Hernandez-Gallego J. Sensory ganglionopathy as a manifestation of celiac disease [Article in Spanish]. Rev Neurol 2007;45(2):91-4. PMID 17642049
18: Fargeot G, Echaniz-Laguna A. Sensory neuronopathies: new genes, new antibodies and new concepts. J Neurol Neurosurg Psychiatry 2021. [Epub ahead of print] PMID 33563795
19: Franca MC Jr, D'Abreu A, Zanardi VA, et al. MRI shows dorsal lesions and spinal cord atrophy in chronic sensory neuronopathies. J Neuroimaging 2008;18(2):168-72. PMID 18380696
20: Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol 2010;67(3):330-5. PMID 20212230
21: Gorson KC, Herrmann DN, Thiagarajan R, et al. Non-length dependent small fibre neuropathy/ganglionopathy. J Neurol Neurosurg Psychiatry 2008;79(2):163-9. PMID 17911181
22: Graus F, Bonaventura I, Uchuya M, et al. Indolent anti-Hu-associated paraneoplastic sensory neuropathy. Neurology 1994;44(12):2258-61. PMID 7991109
23: Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124(Pt 6):1138-48. PMID 11353730
24: Griffin JW, Cornblath DR, Alexander E, et al. Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjogren's syndrome. Ann Neurol 1990;27(3):304-15. PMID 2327738
25: Gwathmey KG. Sensory neuronopathies. Muscle Nerve 2016;53(1):8-19. PMID 26467754
26: Hadjivassiliou M, Rao DG, Wharton SB, Sanders DS, Grunewald RA, Davies-Jones AG. Sensory ganglionopathy due to gluten sensitivity. Neurology 2010;75(11):1003-8. PMID 20837968
27: Kawagashira Y, Koike H, Fujioka Y, et al. Differential, size-dependent sensory neuron involvement in the painful and ataxic forms of primary Sjogren's syndrome-associated neuropathy. J Neurol Sci 2012;319(1-2):139-46. PMID 22658898
28: Koike H, Atsuta N, Adachi H, et al. Clinicopathological features of acute autonomic and sensory neuropathy. Brain 2010;133(10):2881-96. PMID 20736188
29: Kovvuru S, Cardenas YC, Huttner A, Nowak RJ, Roy B. Clinical characteristics of fibroblast growth factor receptor 3 antibody-related polyneuropathy: a retrospective study. Eur J Neurol 2020;27(7):1310-8. PMID 32068339
30: Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rorth M, Krarup C. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007;130(Pt 4):1076-88. PMID 17301082
31: Kuntzer T, Antoine JC, Steck AJ. Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies). Muscle Nerve 2004;30(3):255-68. PMID 15318336
32: Kusunoki S, Shimizu J, Chiba A, Ugawa Y, Hitoshi S, Kanazawa I. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 1996;39(4):424-31. PMID 8619520
33: Lauria G, Pareyson D, Grisoli M, Sghirlanzoni A. Clinical and magnetic resonance imaging findings in chronic sensory ganglionopathies. Ann Neurol 2000;47(1):104-9. PMID 10632108
34: Lauria G, Pareyson D, Sghirlanzoni A. Neurophysiological diagnosis of acquired sensory ganglionopathies. Eur Neurol 2003;50(3):146-52. PMID 14530620
35: Lauria G, Sghirlanzoni A, Lombardi R, Pareyson D. Epidermal nerve fiber density in sensory ganglionopathies: clinical and neurophysiologic correlations. Muscle Nerve 2001;24(8):1034-9. PMID 11439378
36: Lax NZ, Whittaker RG, Hepplewhite PD, et al. Sensory neuronopathy in patients harbouring recessive polymerase gamma mutations. Brain 2012;135(Pt 1):62-71. PMID 22189570
37: Lefaucheur JP, Brusa A, Creange A, Drouot X, Jarry G. Clinical application of laser evoked potentials using the Nd:YAG laser. Neurophysiol Clin 2002;32(2):91-8. PMID 12035490
38: Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004;29(3):387-92. PMID 14981738
39: Mariani LL, Lozeron P, Theaudin M, et al. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 2015;78(6):901-16. PMID 26369527
40: Martinez ARM, Casseb RF, Martins CR Jr, Nucci A, Franca MC Jr. Sensory neuronopathy heralding human T cell lymphotropic virus type I myelopathy. J Neurovirol 2018a;24(3):369-71. PMID 29318453
41: Martinez ARM, Costa MCM, Novaes MAC, Lima HC, Nucci A, Franca MC Jr. A novel phenotype Of Zika virus-related neurological disease: sensory neuronopathy. Muscle Nerve 2018b;57(2):E100-E1. PMID 28877553
42: Martinez ARM, Martins MP, Martins CR Jr, et al. Sensory ataxia rating scale: Development and validation of a functional scale for patients with sensory neuronopathies. J Peripher Nerv Syst 2019;24(3):242-6. PMID 31222873
43: McDonald ES, Randon KR, Knight A, Windebank AJ. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 2005;18(2):305-13. PMID 15686959
44: McKelvie PA, Gates PC, Day T. Canomad: report of a case with a 40-year history and autopsy. Is this a sensory ganglionopathy with neuromuscular junction blockade? Muscle Nerve 2013;48(4):599-603. PMID 23649749
45: McQuade RM, Stojanovska V, Bornstein JC, Nurgali K. PARP inhibition in platinum-based chemotherapy: chemopotentiation and neuroprotection. Pharmacol Res 2018;137:104-13. PMID 30278221
46: Merchut MP, Adams EM, Morrissey M. Sensory neuronopathy in autoimmune chronic active hepatitis. Neurology 1993;43(11):2410-1. PMID 8232969
47: Mori K, Iijima M, Koike H, et al. The wide spectrum of clinical manifestations in Sjogren's syndrome-associated neuropathy. Brain 2005;128(Pt 11):2518-34. PMID 16049042
48: Mori K, Koike H, Misu K, Hattori N, Ichimura M, Sobue G. Spinal cord magnetic resonance imaging demonstrates sensory neuronal involvement and clinical severity in neuronopathy associated with Sjogren's syndrome. J Neurol Neurosurg Psychiatry 2001;71(4):488-92. PMID 11561032
49: Moritz CP, Tholance Y, Lassabliere F, Camdessanche JP, Antoine JC. Reducing the risk of misdiagnosis of indirect ELISA by normalizing serum-specific background noise: The example of detecting anti-FGFR3 autoantibodies. J Immunol Methods 2019;466:52-6. PMID 30654043
50: Moritz CP, Tholance Y, Vallayer PB, et al. Anti-AGO1 antibodies identify a subset of autoimmune sensory neuronopathy. Neurol Neuroimmunol Neuroinflamm 2023;10(3):ee200105. PMID 37072227
51: Morizot-Koutlidis R, Andre-Obadia N, Antoine JC, et al. Somatosensory evoked potentials in the assessment of peripheral neuropathies: commented results of a survey among French-speaking practitioners and recommendations for practice. Neurophysiol Clin 2015;45(2):131-42. PMID 25957985
52: Nagarajan E, Kang SA, Holmes C, Govindarajan R. Clinical features with anti fibroblast growth factor receptor 3 (FGFR3) antibody-related polyneuropathy: a retrospective study. BMC neurology 2021;21(1):74. PMID: 33588772
53: Obi T, Murakami T, Takatsu M, et al. Clinicopathological study of an autopsy case with sensory-dominant polyradiculoneuropathy with antiganglioside antibodies. Muscle Nerve 1999;22(10):1426-31. PMID 10487910
54: Oh SJ, Gurtekin Y, Dropcho EJ, King P, Claussen GC. Anti-Hu antibody neuropathy: a clinical, electrophysiological, and pathological study. Clin Neurophysiol 2005;116(1):28-34. PMID 15589180
55: Pandolfo M. Friedreich ataxia. Arch Neurol 2008;65(10):1296-303. PMID 18852343
56: Pandolfo M. Friedreich ataxia: the clinical picture. J Neurol 2009;256 Suppl 1:3-8. PMID 19283344
57: Pereira PR, Viala K, Maisonobe T, et al. Sjogren sensory neuronopathy (Sjogren ganglionopathy): long-term outcome and treatment response in a series of 13 cases. Medicine (Baltimore) 2016;95(19):e3632. PMID 27175675
58: Rafehi H, Szmulewicz DJ, Bennett MF, et al. Bioinformatics-based identification of expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS. Am J Hum Genet 2019;105(1):151-65. PMID 31230722
59: Rubin DI, Daube JR. Subacute sensory neuropathy associated with Epstein-Barr virus. Muscle Nerve 1999;22(11):1607-10. PMID 10514244
60: Sancho Saldana A, Mahdi-Rogers M, Hadden RD. Sensory neuronopathies: A case series and literature review. J Peripher Nerv Syst 2021;26(1):66-74. PMID 33491284
61: Satake M, Nakagawa Y, Yamashita S, et al. Subacute autonomic and sensory ganglionopathy: a postmortem case. J Neurol Neurosurg Psychiatry 1998;64(4):561. PMID 9576558
62: Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med 1983;309(8):445-8. PMID 6308447
63: Schulte C, Synofzik M, Gasser T, Schols L. Ataxia with ophthalmoplegia or sensory neuropathy is frequently caused by POLG mutations. Neurology 2009;73(11):898-900. PMID 19752458
64: Serrano-Munuera C, Rojas-Garcia R, Gallardo E, et al. Antidisialosyl antibodies in chronic idiopathic ataxic neuropathy. J Neurol 2002;249(11):1525-8. PMID 12420092
65: Sghirlanzoni A, Pareyson D, Lauria G. Sensory neuron diseases. Lancet Neurol 2005;4(6):349-61. PMID 15907739
66: Sinnreich M, Klein CJ, Daube JR, Engelstad J, Spinner RJ, Dyck PJ. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology 2004;63(9):1662-9. PMID 15534252
67: Szmulewicz DJ, McLean CA, Rodriguez ML, et al. Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS. Neurology 2014;82(16):1410-5. PMID 24682971
68: Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006;27(6):992-1002. PMID 16797073
69: Tholance Y, Moritz CP, Rosier C, et al. Clinical characterisation of sensory neuropathy with anti-FGFR3 autoantibodies. J Neurol Neurosurg Psychiatry 2020;91(1):49-57. PMID 31690697
70: Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011;18(1):19-e3. PMID 20880069
71: Trevino JA, Novak P. TS-HDS and FGFR3 antibodies in small fiber neuropathy and Dysautonomia. Muscle Nerve 2021;64(1):70-6. PMID 33792960
72: Usoskin D, Furlan A, Islam S, et al. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. Nat Neurosci 2015;18(1):145-53. PMID 25420068
73: Willison HJ, O'Leary CP, Veitch J, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 2001;124(Pt 10):1968-77. PMID 11571215
74: Windebank AJ, Blexrud MD, Dyck PJ, Daube JR, Karnes JL. The syndrome of acute sensory neuropathy: clinical features and electrophysiologic and pathologic changes. Neurology 1990;40(4):584-91. PMID 2157173

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Jean-Christophe Antoine MD

Dr. Antoine of University Hospital of Saint-Etienne, France, has no relevant financial relationships to disclose.
See Profile

Editor

Francesc Graus MD PhD

Dr. Graus, Emeritus Professor, Laboratory Clinical and Experimental Neuroimmunology, Institut D’Investigacions Biomédiques August Pi I Sunyer, Hospital Clinic, Spain, has no relevant financial relationships to disclose.
See Profile

Former Authors

Kyoko Saida MD (original author)

Patient Profile

Age range of presentation: 19 to 65+ years
Sex preponderance: female > male: sensory neuronopathy with autoimmune disease

male > female: paraneoplastic sensory neuronopathy
Heredity: none
Population groups selectively affected: paraneoplastic sensory neuronopathy: smoking people at risk for lung cancer

dysimmune sensory neuronopathy: people with an associated autoimmune disease
Occupation groups selectively affected: none

ICD & OMIM codes

ICD-9: disorders of the peripheral nervous system: 350-359

Idiopathic progressive polyneuropathy: 356.4

Polyneuropathy in collagen vascular disease: 357.1

Polyneuropathy due to other toxic agents: 357.7

polyneuropathy, unspecified: 357.9
ICD-10: polyneuropathy and other PNS disorders: G60-G64

inflammatory polyneuropathy, unknown: G61.9

polyneuropathy associated with neoplasm: C00-D48+ C34.9,C70.1

polyneuropathy associated with systemic collagen vascular disorder: G63.5 M30-M35+

polyneuropathy associated with endocrine and metabolic diseases: G63.3 E03.9, E14

polyneuropathy with other infections and parasites: G63.0, A30.8, A52.1, B23.8

polyneuropathy associated with nutritional deficiencies: G63.4 E67.2, E56.0

polyneuropathy related to hereditary ataxias: G60.2

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Acquired sensory neuronopathies

Associated Disorders

autoimmune disorders
autonomic ganglionopathy
cancer
lung cancer
chemotherapy
- Hodgkin’s disease
- breast cancer
- malignant tumors
- paraneoplastic encephalomyelitis
- rheumatoid arthritis
- Sjögren syndrome
- autoimmune hepatitis
- celiac disease
- viral infections

Differential Diagnosis

vitamin E deficiency
vasculitis
Friedreich ataxia
hereditary sensory neuropathy
hereditary amyloid polyneuropathy
- Charcot-Marie-Tooth diseases
- POLG-related syndrome (SANDO)
- CANVAS (cerebellar ataxia, neuropathy, vestibular areflexia syndrome)
- Guillain-Barré syndrome
- chronic inflammatory demyelinating polyneuropathy
- chronic immune sensory polyradiculopathy

Also Relevant

Guillain-Barre syndrome
Paraneoplastic sensory neuronopathy
Sensory neuropathies associated with anti-GD1b ganglioside antibodies
Sjogren syndrome: neurologic complications
Small fiber neuropathies

Acquired sensory neuronopathies

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Table 1. Hereditary/Genetic Sensory Neuronopathies That May Present at Least For a Time as Sporadic Cases of Adult Onset Sensory Neuropathy

Diagnostic workup

Table 2. Diagnostic Criteria of Sensory Neuronopathy

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Autoantibodies: mechanism and testing

Multiple sclerosis: treatment of its symptoms

Anti-GQ1b antibody syndrome

Paraneoplastic syndromes

Anti-IgLON5 disease

Balo concentric sclerosis

Anti-LGI1 encephalitis

Progressive encephalomyelitis with rigidity and myoclonus and glycine receptor antibodies

This is an article preview.
Start a Free Account
to access the full version.